ClinicalTrials.Veeva

Find clinical trials for Non-Hodgkin Lymphoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Paris, Île-de-France, FRA:

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Paris, France and 88 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Paris, France and 72 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Paris 10, France and 66 other locations

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Villejuif, France and 26 other locations

intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Biological: UCART20x22
Biological: CLLS52

Phase 1, Phase 2

Cellectis

Paris, Ile De France, France and 8 other locations

Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with adva...

Active, not recruiting
Lymphoma, Non-Hodgkin
Neoplasms
Drug: CC-90011
Drug: Itraconazole

Phase 1

Celgene
Celgene

Villejuif Cedex, France and 14 other locations

or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation par...

Active, not recruiting
Lymphoma, Non-Hodgkin
Neoplasms
Drug: CC-90010

Phase 1

Celgene
Celgene

Villejuif, France and 10 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: CC-99282
Drug: Rituximab

Phase 2

AbbVie
AbbVie

Paris, Ile-de-France, France and 73 other locations

study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Villejuif Cedex, France and 16 other locations

of BMS-986458 as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin...

Enrolling
Relapsed/Refractory Non-Hodgkin Lymphoma
Drug: Rituximab
Drug: BMS-986458

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Villejuif, Paris, France and 15 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems